Calcium Channel Blockers and Dementia

Overview

Journal Br J Pharmacol

Publisher Wiley

Specialty Pharmacology

Date 2013 May 4

PMID 23638877

Citations 58

Authors

V Nimmrich

A Eckert

Affiliations

Soon will be listed here.

Abstract

Degenerative dementia is mainly caused by Alzheimer's disease and/or cerebrovascular abnormalities. Disturbance of the intracellular calcium homeostasis is central to the pathophysiology of neurodegeneration. In Alzheimer's disease, enhanced calcium load may be brought about by extracellular accumulation of amyloid-β. Recent studies suggest that soluble forms facilitate influx through calcium-conducting ion channels in the plasma membrane, leading to excitotoxic neurodegeneration. Calcium channel blockade attenuates amyloid-β-induced neuronal decline in vitro and is neuroprotective in animal models. Vascular dementia, on the other hand, is caused by cerebral hypoperfusion and may benefit from calcium channel blockade due to relaxation of the cerebral vasculature. Several calcium channel blockers have been tested in clinical trials of dementia and the outcome is heterogeneous. Nimodipine as well as nilvadipine prevent cognitive decline in some trials, whereas other calcium channel blockers failed. In trials with a positive outcome, BP reduction did not seem to play a role in preventing dementia, indicating a direct protecting effect on neurons. An optimization of calcium channel blockers for the treatment of dementia may involve an increase of selectivity for presynaptic calcium channels and an improvement of the affinity to the inactivated state. Novel low molecular weight compounds suitable for proof-of-concept studies are now available.

Citing Articles

A small-molecule screen identifies novel aging modulators by targeting 5-HT/DA signaling pathway.

Ye S, Song S, Liu X, Luo Y, Cai S Aging Cell. 2024; 24(3):e14411.

PMID: 39552540 PMC: 11896485. DOI: 10.1111/acel.14411.

Natural L-type calcium channels antagonists from Chinese medicine.

Xu F, Cai W, Liu B, Qiu Z, Zhang X Chin Med. 2024; 19(1):72.

PMID: 38773596 PMC: 11107034. DOI: 10.1186/s13020-024-00944-8.

Bioinformatic Identification of Signaling Pathways and Hub Genes in Vascular Dementia.

Wu Y, Cai J, Pang B, Cao L, He Q, He Q Actas Esp Psiquiatr. 2024; 52(2):83-98.

PMID: 38622006 PMC: 11015743. DOI: 10.62641/aep.v52i2.1601.

Disease phenotypic screening in neuron-glia cocultures identifies blockers of inflammatory neurodegeneration.

Birkle T, Willems H, Skidmore J, Brown G iScience. 2024; 27(4):109454.

PMID: 38550989 PMC: 10973195. DOI: 10.1016/j.isci.2024.109454.

Dysregulation of Ion Channels and Transporters and Blood-Brain Barrier Dysfunction in Alzheimer's Disease and Vascular Dementia.

Liu R, Collier J, Abdul-Rahman N, Capuk O, Zhang Z, Begum G Aging Dis. 2024; 15(4):1748-1770.

PMID: 38300642 PMC: 11272208. DOI: 10.14336/AD.2023.1201.

References

Anekonda T, Quinn J, Harris C, Frahler K, Wadsworth T, Woltjer R . L-type voltage-gated calcium channel blockade with isradipine as a therapeutic strategy for Alzheimer's disease. Neurobiol Dis. 2010; 41(1):62-70. PMC: 2982927. DOI: 10.1016/j.nbd.2010.08.020. View

MacManus A, Ramsden M, Murray M, Henderson Z, Pearson H, Campbell V . Enhancement of (45)Ca(2+) influx and voltage-dependent Ca(2+) channel activity by beta-amyloid-(1-40) in rat cortical synaptosomes and cultured cortical neurons. Modulation by the proinflammatory cytokine interleukin-1beta. J Biol Chem. 2000; 275(7):4713-8. DOI: 10.1074/jbc.275.7.4713. View

Rocca W, Hofman A, Brayne C, Breteler M, Clarke M, Copeland J . Frequency and distribution of Alzheimer's disease in Europe: a collaborative study of 1980-1990 prevalence findings. The EURODEM-Prevalence Research Group. Ann Neurol. 1991; 30(3):381-90. DOI: 10.1002/ana.410300310. View

Nimmrich V, Grimm C, Draguhn A, Barghorn S, Lehmann A, Schoemaker H . Amyloid beta oligomers (A beta(1-42) globulomer) suppress spontaneous synaptic activity by inhibition of P/Q-type calcium currents. J Neurosci. 2008; 28(4):788-97. PMC: 6671006. DOI: 10.1523/JNEUROSCI.4771-07.2008. View

Paris D, Bachmeier C, Patel N, Quadros A, Volmar C, Laporte V . Selective antihypertensive dihydropyridines lower Aβ accumulation by targeting both the production and the clearance of Aβ across the blood-brain barrier. Mol Med. 2010; 17(3-4):149-62. PMC: 3060987. DOI: 10.2119/molmed.2010.00180. View

Rovira C, Arbez N, Mariani J . Abeta(25-35) and Abeta(1-40) act on different calcium channels in CA1 hippocampal neurons. Biochem Biophys Res Commun. 2002; 296(5):1317-21. DOI: 10.1016/s0006-291x(02)02072-7. View

Hunter A . Calcium antagonists: their role in neuroprotection. Int Rev Neurobiol. 1997; 40:95-108. DOI: 10.1016/s0074-7742(08)60717-5. View

Weiss J, Pike C, Cotman C . Ca2+ channel blockers attenuate beta-amyloid peptide toxicity to cortical neurons in culture. J Neurochem. 1994; 62(1):372-5. DOI: 10.1046/j.1471-4159.1994.62010372.x. View

Caudle W, Zhang J . Glutamate, excitotoxicity, and programmed cell death in Parkinson disease. Exp Neurol. 2009; 220(2):230-3. DOI: 10.1016/j.expneurol.2009.09.027. View

10.

Asakura K, Matsuo Y, Kanemasa T, Ninomiya M . P/Q-type Ca2+ channel blocker omega-agatoxin IVA protects against brain injury after focal ischemia in rats. Brain Res. 1998; 776(1-2):140-5. DOI: 10.1016/s0006-8993(97)00975-x. View

11.

Yu L, Edalji R, Harlan J, Holzman T, Lopez A, Labkovsky B . Structural characterization of a soluble amyloid beta-peptide oligomer. Biochemistry. 2009; 48(9):1870-7. DOI: 10.1021/bi802046n. View

12.

Texido L, Martin-Satue M, Alberdi E, Solsona C, Matute C . Amyloid β peptide oligomers directly activate NMDA receptors. Cell Calcium. 2011; 49(3):184-90. DOI: 10.1016/j.ceca.2011.02.001. View

13.

Yu J, Chang R, Tan L . Calcium dysregulation in Alzheimer's disease: from mechanisms to therapeutic opportunities. Prog Neurobiol. 2009; 89(3):240-55. DOI: 10.1016/j.pneurobio.2009.07.009. View

14.

Gellermann G, Byrnes H, Striebinger A, Ullrich K, Mueller R, Hillen H . Abeta-globulomers are formed independently of the fibril pathway. Neurobiol Dis. 2008; 30(2):212-20. DOI: 10.1016/j.nbd.2008.01.010. View

15.

Fu H, Li W, Lao Y, Luo J, Lee N, Kan K . Bis(7)-tacrine attenuates beta amyloid-induced neuronal apoptosis by regulating L-type calcium channels. J Neurochem. 2006; 98(5):1400-10. DOI: 10.1111/j.1471-4159.2006.03960.x. View

16.

Abbadie C, McManus O, Sun S, Bugianesi R, Dai G, Haedo R . Analgesic effects of a substituted N-triazole oxindole (TROX-1), a state-dependent, voltage-gated calcium channel 2 blocker. J Pharmacol Exp Ther. 2010; 334(2):545-55. DOI: 10.1124/jpet.110.166363. View

17.

Yagami T, Ueda K, Asakura K, Sakaeda T, Nakazato H, Kuroda T . Gas6 rescues cortical neurons from amyloid beta protein-induced apoptosis. Neuropharmacology. 2003; 43(8):1289-96. DOI: 10.1016/s0028-3908(02)00333-7. View

18.

OBrien J, Erkinjuntti T, Reisberg B, Roman G, Sawada T, Pantoni L . Vascular cognitive impairment. Lancet Neurol. 2003; 2(2):89-98. DOI: 10.1016/s1474-4422(03)00305-3. View

19.

Salomone S, Caraci F, Leggio G, Fedotova J, Drago F . New pharmacological strategies for treatment of Alzheimer's disease: focus on disease modifying drugs. Br J Clin Pharmacol. 2011; 73(4):504-17. PMC: 3376428. DOI: 10.1111/j.1365-2125.2011.04134.x. View

20.

Jacobsen J, Wu C, Redwine J, Comery T, Arias R, Bowlby M . Early-onset behavioral and synaptic deficits in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A. 2006; 103(13):5161-6. PMC: 1405622. DOI: 10.1073/pnas.0600948103. View